National audit assessing the management of rectal cancer during the COVID-19 pandemic launches with 30 sites registered.
The ReCaP Study is an ACPGBI endorsed sub-study of the IMPACT Audit. IMPACT aims to improve standards in MDT management of patients with locally advanced and recurrent rectal cancer in the UK.
ReCaP will study decision-making and strategy for patients with rectal cancer, which will progress to a formal longitudinal cohort study to assess both the long term oncological and patient centred effects of the pandemic. There will be four phases:
- UK multi-centre audit of MDT decision-making
- Short-term outcomes and patient experience
- Three-year QoL
- Data linkage
Further details: IMPACT.ReCaP1@gmail.com
Follow the study on Twitter: @IMPACT_ReCaP
